Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Agenus is a leading US biopharmaceutical company specializing in the discovery and development of innovative immuno-oncology therapies. The company focuses on novel approaches to cancer treatment, including immune checkpoint modulators, cell therapies, and vaccines. With a robust pipeline, Agenus aims to deliver groundbreaking medicines and sustainably improve the lives of cancer patients.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Agenus is scheduled to report its next quarterly earnings on 11/10/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Agenus last reported quarterly earnings on 8/6/2026 (Q2 2026). Earnings per share (EPS) came in at -0.01 USD.
Across its last 3 earnings reports, Agenus stock moved by ±8.9% on average the following day. The largest reaction was -14.7% on 05/11/2026; 2 of 3 reactions were positive.
Agenus has beaten analyst EPS estimates in 1 of its last 5 evaluated quarters (beat rate: 20%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.